Reviewer's report

Title: Reversible Posterior Leukoencephalopathy Syndrome Induced by Pazopanib.

Version: 1 Date: 23 May 2012

Reviewer: Olivier Mir

Reviewer's report:

Compulsory revisions: none

Essential revisions:

1. The authors mention that blood pressure was high at the time of RPLS. Was there any proteinuria? (a recent review on RPLS in patients receiving anti-VEGF agents mentioned frequent proteinuria in the weeks preceding the occurrence of neurological events; see Tlemsani C, et al. Target Oncol 2011)
2. Was there subsequent hypertension/proteinuria when sorafenib was re-introduced?
3. The authors have used IV mannitol at the acute phase of RPLS. Is this a standardized therapeutic management? if so, please provide a reference.
4. For readers willing to know more on RPLS in patients receiving anti-VEGF agents, please provide the above-mentioned reference (Tlemsani et al.) in the revised manuscript.

Discretionary Revisions: none.

Level of interest: An article of importance in its field

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

I have no conflicts of interest related to this work.

Otherwise, I have acted as board member for Roche, and paid consultant for Roche, Pfizer, Servier, Bayer.